Asia Pacific Overactive Bladder Treatment Market

The Asia Pacific overactive bladder treatment market is expected to grow from US$ 871.48 million in 2022 to US$ 1,082.25 million by 2028; it is estimated to grow at a CAGR of 3.7% from 2022 to 2028.  

Robust Pipeline of Drugs and Successive Launch of Novel Therapies to Bolster Asia Pacific Overactive Bladder Treatment 

In December 2020, a new drug application was approved for Gemtesa, a beta 3-agonist and a novel treatment for overactive bladder in adults. Gemtesa (vibegron), provided by Urovant Sciences, helps in relaxing the detrusor bladder muscle, which enables the bladder to hold more urine; the relaxation of this muscle reduces overactive bladder symptoms. It is a once-daily pill and the first overactive bladder medication that does not require dose titration. Many universities and academic institutions are conducting robust research and development activities on novel molecules to treat OAB. For instance, the Yonsei University College of Medicine and Severance Hospital, Seoul, South Korea, is evaluating DA8010, a novel muscarinic M3 receptor antagonist. In September 2021, the university published that in the phase 2 trial, the M3 antagonist DA8010 was demonstrated for the efficacy and safety of overactive bladder treatment. The robust pipeline of drugs for overactive bladder treatment and the successive launch of novel drugs and therapies are expected to drive the growth of the Asia Pacific overactive bladder treatment market in the coming years.     

Asia Pacific Overactive Bladder Treatment Market Overview

The Asia Pacific overactive bladder treatment market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. The market growth is attributed to the rising geriatric population, increasing urinary incontinence cases, and a growing number of product launches. Overactive bladder is caused due to abdominal trauma, urinary infection, urinary incontinence, and nerve damage. According to National Centre for Biotechnology (NCBI), in 2019, 1 in 5 individuals above 40 years was identified with symptoms of overactive bladder syndrome in China. The Chinese Medical Journal stated that the rate of overactive bladder cases was 5.9% among people over 18 years in 2019. According to World Health Organization, people aged 60 years in China are expected to grow from 10% in 2021 to 28% by 2041. Further, as per the World Population Aging 2019, in Hong Kong, people aged 60 years and older accounted for 17.5% of the total population in 2019. With the growing geriatric population, the number of patients having an overactive bladder and urinary tract infection is expected to increase in the coming years. All these factors are contributing to the Asia Pacific overactive bladder treatment market growth.

Asia Pacific Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

 

Asia Pacific Overactive Bladder Treatment Strategic Insights

Strategic insights for the Asia Pacific Overactive Bladder Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Overactive Bladder Treatment Report Scope

Asia Pacific Overactive Bladder Treatment Regional Insights

The geographic scope of the Asia Pacific Overactive Bladder Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Overactive Bladder Treatment Market Segmentation

The Asia Pacific overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the Asia Pacific overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the Asia Pacific overactive bladder treatment market in 2022.   

Based on disease type, the Asia Pacific overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the Asia Pacific overactive bladder treatment market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.   

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific overactive bladder treatment market.